Angiotensin II antagonists for hypertension: are there differences in efficacy?

[1]  P. Howe,et al.  The Antihypertensive Efficacy of the Combination of Irbesartan and Hydrochlorotfflazide Assessed by 24-Hour Ambulatory Blood Pressure Monitoring , 1999 .

[2]  T. Bunt.  An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. , 1999, Clinical therapeutics.

[3]  S. Oparil,et al.  Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. , 1998, The American journal of cardiology.

[4]  T. Bunt.  Problems with interpreting the data in Kassler-Taub et al's article comparing irbesartan and losartan. , 1999, American journal of hypertension.

[5]  Y. Lacourciére,et al.  The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study Group. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[6]  B. Bloom.  Continuation of initial antihypertensive medication after 1 year of therapy. , 1998, Clinical therapeutics.

[7]  B. Martina,et al.  Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on blood pressure and peripheral capillary microcirculation in patients with mild-to-moderate hypertension , 1998, Journal of Human Hypertension.

[8]  A. Vahlbruch,et al.  Efficacy, safety, and effects on hypertension-associated symptoms of losartan, alone or in combination with hydrochlorothiazide, versus amlodipine in patients with mild-to-moderate hypertension , 1998 .

[9]  R. Reeves,et al.  Dose-related efficacy of irbesartan for hypertension: an integrated analysis. , 1998, Hypertension.

[10]  H. Black,et al.  D006 The combination of valsartan and hydrochlorothiazide is effective and well tolerated in essential hypertension , 1998 .

[11]  C. A. Zuschke,et al.  E046: The angiotensin-II receptor blocker candesartan cilexetil provides 24-hour blood pressure control with once-a-day administration in mild-to-moderate hypertension , 1998 .

[12]  G. Mcinnes.  E056: Combination of candesartan cilexetil/hydrochlorothiazide 8/12.5 mg has a similar antihypertensive effect and is better tolerated than lisinopril/hydrochlorothiazide 10/12.5 mg , 1998 .

[13]  P. Raskin,et al.  Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. , 1998, American journal of hypertension.

[14]  D. Sprecher,et al.  Efficacy and Tolerability of Irbesartan, an Angiotensin II Receptor Antagonist, in Primary Hypertension , 1998 .

[15]  L. Ruilope,et al.  A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension , 1998, Journal of Human Hypertension.

[16]  M. Osbakken,et al.  Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. , 1998, Blood pressure.

[17]  S. Neldam,et al.  The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. , 1998, Blood pressure.

[18]  S. Oparil,et al.  Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. , 1998, The American journal of cardiology.

[19]  A. Veld.  Clinical overview of irbesartan: expanding the therapeutic window in hypertension. , 1997 .

[20]  J. Flack,et al.  Effects and Tolerability of Irbesartan Versus Enalapril in Patients With Severe Hypertension fn1 , 1997 .

[21]  P. Sever.  Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil , 1997, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[22]  A. Markham,et al.  Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. , 1997, Drugs.

[23]  A. Zanchetti,et al.  24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. Irbesartan Multicenter Investigators' Group. , 1997, Journal of hypertension.

[24]  H. Pouleur.  Clinical overview of irbesartan: a new angiotensin II receptor antagonist. , 1997, American journal of hypertension.

[25]  P. Pentikäinen,et al.  Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well‐being , 1997, Journal of hypertension.

[26]  A. Bremner,et al.  Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. , 1997, Clinical and experimental hypertension.

[27]  G. Mcinnes,et al.  The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. , 1997, Journal of human hypertension.

[28]  T. Philipp,et al.  Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. , 1997, Journal of human hypertension.

[29]  P. Sever.  Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. , 1997, Journal of human hypertension.

[30]  A. Zanchetti,et al.  Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. , 1997, Journal of human hypertension.

[31]  H. Franke.  Antihypertensive effects of candesartan cilexetil, enalapril and placebo. , 1997, Journal of human hypertension.

[32]  D. Elmfeldt,et al.  Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. , 1997, Journal of human hypertension.

[33]  K. Goa,et al.  Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. , 1997, Drugs.

[34]  Heath,et al.  Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. , 1997, Blood pressure monitoring.

[35]  J. Levine,et al.  Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril , 1997, Journal of Human Hypertension.

[36]  S. Oparil,et al.  H29: Comparison of the efficacy of two angiotensin II antagonists, valsartan and losartan, in essential hypertension , 1997 .

[37]  C. J. Zablocki,et al.  D5 Irbesartan in combination with hydrochlorothiazide in mild-to-moderate hypertension , 1997 .

[38]  K. Kawecka-Jaszcz,et al.  H13 Antihypertensive effects and tolerability of candesartan cilexetil, amlodipine and their combination , 1997 .

[39]  R. Rohde,et al.  D4 Safety and efficacy of irbesartan in hypertensive patients with type II diabetes and proteinuria , 1997 .

[40]  C. Sweet,et al.  Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension. , 1997, Blood pressure.

[41]  A. J. Man in't veld.  Clinical overview of irbesartan: expanding the therapeutic window in hypertension. , 1997, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[42]  J. Flack,et al.  Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators. , 1997, The American journal of cardiology.

[43]  R. Cífková,et al.  A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension. , 1997, Acta cardiologica.

[44]  J. Reid,et al.  Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. , 1997, Pharmacology & therapeutics.

[45]  U. Gundert-Remy,et al.  Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension – a population analysis , 1997, European Journal of Clinical Pharmacology.

[46]  J. Sullivan,et al.  Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide , 1997, European Journal of Clinical Pharmacology.

[47]  S. Oparil,et al.  The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. , 1996, Clinical therapeutics.

[48]  R. Fogari,et al.  Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril , 1996, Journal of hypertension.

[49]  R. Fogari,et al.  Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine , 1996, Clinical pharmacology and therapeutics.

[50]  S. Oparil,et al.  Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. , 1996, Clinical therapeutics.

[51]  J. Critchley,et al.  A randomized, double-masked comparison of the antihypertensive efficacy and safety of combination therapy with losartan and hydrochlorothiazide versus captopril and hydrochlorothiazide in elderly and younger patients , 1996 .

[52]  J. Edelman,et al.  Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. , 1996, Clinical therapeutics.

[53]  Jonas H. Ellenberg,et al.  Intent-to-Treat Analysis versus As-Treated Analysis , 1996 .

[54]  S. Snapinn,et al.  Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. , 1996, Archives of internal medicine.

[55]  L. Ruilope,et al.  Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. , 1996, Blood pressure.

[56]  K. Goa,et al.  Losartan potassium , 1996 .

[57]  B. Trimarco.  [The first clinical experience in Italy with angiotensin II receptor antagonists: results of a multicenter study on the efficacy and tolerance in arterial hypertension]. , 1995, Cardiologia.

[58]  I. Tikkanen,et al.  Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension , 1995, Journal of hypertension.

[59]  J. Edelman,et al.  Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. , 1995, Clinical therapeutics.

[60]  J. Chan,et al.  Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. , 1995, Journal of human hypertension.

[61]  C. Sweet,et al.  Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension , 1995, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[62]  R. Byyny.  Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring , 1995, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[63]  D. Snavely,et al.  A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. , 1995, Hypertension.

[64]  B. Dahlöf,et al.  Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. , 1995, American journal of hypertension.

[65]  L. Passman,et al.  The treatment of mild hypertension study. , 1993, JAMA.

[66]  E. Nelson,et al.  The treatment of mild hypertension study. , 1993, JAMA.

[67]  C. Lewis,et al.  Treatment of Mild Hypertension Study: Final Results , 1993 .

[68]  J. Cutler,et al.  Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. , 1993, JAMA.

[69]  D. Faulds,et al.  Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension. , 1992, Drugs.